JusticeItaly Official institution
Italy revokes marketing authorization for Doxorubicina Liposomiale Pegilata Dr. Reddy's at company's request
Italy's medicines agency, AIFA, has revoked the marketing permission for the human medicine Doxorubicina Liposomiale Pegilata Dr. Reddy's. The license holder gave up the authorization voluntarily, and the notice is listed under reference 26A05660. The excerpt does not give a date for the revocation.
This summary was generated by AI; the official source prevails.
What does it mean?
Italy's medicine regulator has withdrawn its permission for the cancer drug Doxorubicina Liposomiale Pegilata Dr. Reddy's, so it can no longer be sold there under that approval. The company that held the approval asked for this itself.
Who is affected?
Patients and pharmacies in Italy who rely on this drug, and the company that held its marketing permission.